Bertino Gaetano, Malaguarnera Giulia, Frazzetto Evelise, Sciuto Alice, Inserra Gaetano, Zanghì Guido Nicola, Malaguarnera Michele
Hepatology Unit, Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Catania 95123, Italy.
Research Center "the Great Senescence", University of Catania, Catania 95100, Italy.
World J Hepatol. 2018 Jun 27;10(6):448-451. doi: 10.4254/wjh.v10.i6.448.
There are several causes of hepatocellular carcinoma (HCC), but certainly the hepatitis C virus (HCV) is one of the most common. The HCV is able to contribute, both directly and indirectly, to the development of HCC. Determining early HCV clearance before an advanced liver disease develops, is absolutely necessary as this prevents the initiation of the cascade of events induced by HCV that may result in the development of HCC. The early treatment of the infection and the clearance of HCV represents today, in the age of the direct antiviral agents (DAAs), an extraordinary opportunity for true prevention of the development of HCV-related HCC.
肝细胞癌（HCC）有多种病因，但丙型肝炎病毒（HCV）无疑是最常见的病因之一。HCV能够直接或间接促进HCC的发生。在晚期肝病发展之前确定HCV早期清除是绝对必要的，因为这可防止由HCV诱导的一系列事件的发生，而这些事件可能导致HCC的发展。在直接抗病毒药物（DAA）时代，对HCV感染进行早期治疗并清除病毒，为真正预防HCV相关HCC的发生提供了一个绝佳机会。
